News

As dividend investors know, there's an upside to investing in a big pharmaceutical business like Amgen (NASDAQ: AMGN) for dividend income. It likely has the resources and proven capabilities that'll

As dividend investors know, there's an upside to investing in a big pharmaceutical business like Amgen (NASDAQ: AMGN) for dividend income. It likely has the resources and proven capabilities that'll

As dividend investors know, there's an upside to investing in a big pharmaceutical business like Amgen (NASDAQ: AMGN) for dividend income. It likely has the resources and proven capabilities that'll

Like many of the biotechs pursuing coronavirus vaccine development, Novavax (NASDAQ: NVAX) has seen better days. Its shares are down by 96% over the past three years, and the company's remaining

Famed investor Warren Buffett once said he aimed to be greedy when others were fearful. Here's one way to apply this bit of advice when investing in stocks: Equities that look beaten-down can be

Famed investor Warren Buffett once said he aimed to be greedy when others were fearful. Here's one way to apply this bit of advice when investing in stocks: Equities that look beaten-down can be

With the S&P 500 index recently hitting a new all-time high, we can officially declare that we are in a bull market. While that's exciting news, it doesn't change the blueprint of success for

What's the appeal of investing in relatively small and little-known corporations? Though these businesses come with heightened risks, getting in on the ground floor can potentially be lucrative over

What's the appeal of investing in relatively small and little-known corporations? Though these businesses come with heightened risks, getting in on the ground floor can potentially be lucrative over

What's the appeal of investing in relatively small and little-known corporations? Though these businesses come with heightened risks, getting in on the ground floor can potentially be lucrative over

Novavax (NASDAQ: NVAX) shares have offered investors a roller coaster ride over the past few years. They soared more than 2,700% in early pandemic days as investors bet on the company's

Pfizer (NYSE: PFE) has reached a major transition point. The big pharma company took center stage earlier in the COVID-19 pandemic when it became the first to launch a coronavirus vaccine. That

Pfizer (NYSE: PFE) has reached a major transition point. The big pharma company took center stage earlier in the COVID-19 pandemic when it became the first to launch a coronavirus vaccine. That

A few years ago, biotech company Novavax (NASDAQ: NVAX) looked like a promising stock. It emerged as a leader in the development of a COVID-19 vaccine, which sent its share price through the roof.

I'll readily admit that I've picked some supposed growth stocks in the past that didn't deliver much growth. The good news, though, is that my winners have far outpaced my losers over the long run.

I'll readily admit that I've picked some supposed growth stocks in the past that didn't deliver much growth. The good news, though, is that my winners have far outpaced my losers over the long run.

I'll readily admit that I've picked some supposed growth stocks in the past that didn't deliver much growth. The good news, though, is that my winners have far outpaced my losers over the long run.

Cancer bites, but Amgen (NASDAQ: AMGN) is going to keep biting back. In fact, it's currently developing a handful of oncology medicines that it describes as bispecific T-cell engager therapies, or

Cancer bites, but Amgen (NASDAQ: AMGN) is going to keep biting back. In fact, it's currently developing a handful of oncology medicines that it describes as bispecific T-cell engager therapies, or

Cancer bites, but Amgen (NASDAQ: AMGN) is going to keep biting back. In fact, it's currently developing a handful of oncology medicines that it describes as bispecific T-cell engager therapies, or

Companies focusing on developing gene editing therapies have made significant progress over the past year. However, that has done little to keep Intellia Therapeutics (NASDAQ: NTLA) afloat. The